Researchers have unveiled a complex interplay between liver X and thyroid hormone receptors that regulates critical brain functions and protects against neurodegeneration. LXRs play a crucial role in regulating thyroid hormone function in the brain, while both receptors are essential for normal brain development and maintenance.
Researchers have identified liver X receptor beta as a promising target for treating depression and anxiety, with key findings including LXRβ's role in regulating neurotransmission and neurogenesis. This breakthrough could lead to novel therapies for treatment-resistant depression and personalized medicine approaches in psychiatry.
Researchers have uncovered a shared genetic basis for bipolar disorder type I and epilepsy, identifying 1,300 genetic variants influencing both conditions. The study suggests that mood stabilizers may be effective in treating both illnesses, and could lead to personalized medicine approaches.
Researchers identify a homozygous SPAG9 gene mutation associated with intellectual disability, progressive cognitive decline, and heterogeneous brain abnormalities. The study provides a unique model for understanding disruptions in cellular transport mechanisms leading to neurodevelopmental and degenerative brain conditions.
A new study reveals how psilocybin alters brain connectivity to alleviate symptoms of body dysmorphic disorder, potentially aiding treatment. Psilocybin strengthens neural connections between executive functions and emotionally salient stimuli, leading to improved BDD symptoms.
Researchers have found that ultra-short heart rate variability measures can accurately capture autonomic function in severe TBI survivors using 30-60 second recordings. The study validates the reliability of these ultra-short HRV measures, which may provide an objective marker for post-TBI autonomic health.
Researchers have proposed a novel treatment strategy for post-acute infectious syndromes (PAIS), including Long COVID. The multimodal approach combines pharmacological interventions like metformin and low-dose naltrexone with physical therapies like extracorporeal apheresis.
A new viewpoint review explores the impact of TAAR1 genetic variations on mental health and drug development. The study suggests that rare TAAR1 mutations may contribute to psychiatric symptoms by altering brain function.
A comprehensive review highlights key findings on the complex relationship between genes and environment in schizophrenia risk, including polygenic risk scores and gene-environment interactions. The study emphasizes the importance of large cohorts and emerging tools to capture the full complexity of schizophrenia risk.
A comprehensive review of genetic and population studies challenges conventional wisdom about the relationship between genetic risk and cognitive deficits in schizophrenia. Premorbid cognitive impairment is largely explained by non-familial factors rather than inherited genetic variants.
Dr. Lutz's pioneering research combines genetic engineering, multiomics, and bioinformatics to understand epigenetic mechanisms underlying psychiatric conditions like addiction and depression. His work aims to bridge the gap between genomics and behavior.
A new study suggests that psychedelics like psilocybin can suppress learned fear responses in individuals with PTSD by altering activity in the amygdala, a key brain region involved in processing fear and anxiety. The findings propose that psychedelic drugs enhance inhibitory signaling from GABAergic interneurons onto excitatory neurons.